Antibodies binding to phosphorylcholine (pc) and/or pc conjugates
AssigneesDyax Corp., Athera Biotechnologies AB
InventorsKnut Pettersson, Ola Camber, Dan Sexton, Andrew E. Nixon
Life of this patent
Estimating the term…
Loading patent…
AssigneesDyax Corp., Athera Biotechnologies AB
InventorsKnut Pettersson, Ola Camber, Dan Sexton, Andrew E. Nixon
Estimating the term…
The present disclosure relates to an antibody or antibody fragment capable of binding to phosphorylcholine and/or a phosphorylcholine conjugate, wherein the antibody or antibody fragment comprises a variable heavy chain (VH) domain and/or a variable light chain (VL) domain, and wherein (a) the VH domain comprises complementarity determining regions (CDRs) selected from the group consisting of: a CDR1 sequence having identity to the sequence of SEQ ID NO: 7; a CDR2 sequence having identity to the sequence of SEQ ID NO: 8; and a CDR3 sequence having identity to the sequence of SEQ ID NO: 9 or 10; and/or (b) the VL domain comprises CDRs selected from the group consisting of: a CDR4 sequence having identity to the sequence of SEQ ID NO: 11; a CDR5 sequence having identity to the sequence of SEQ ID NO: 12; a CDR6 sequence having identity to the sequence of SEQ ID NO: 13.
An antibody or antibody fragment capable of binding to phosphorylcholine and/or a phosphorylcholine conjugate,
A pharmaceutical composition comprising or consisting essentially of an antibody or an antibody fragment according to any of the preceding claims and a pharmaceutically acceptable carrier or excipient, optionally wherein the only antibodies or antibody fragments present in the composition are those defined by any of the preceding claims.
19-22. (canceled)
Dependencies are inferred from the claim text.